CHTP..$2.83..had a pullback to $2.74 but it is gone for now. Pullbacks will be fewer as this one should start to move soon over the next few weeks IMO. 207K in volume so far.
Roth Capital optimistic on Chelsea Therapeutics (note from last week)
-The important takeaway from Chelsea Therapeutics' Q2 report is that the re-filing for Northera remains on track for this month, Roth Capital says, maintaining a Buy rating and a $4 price target.
-Late last month the FDA identified certain "technical deficiencies" in the NDA for Northera.
There are "no surprises in the 10-Q," and "the risk/reward" is favorable for "risk-tolerant investors," Roth adds.
Market Data 
Markets 
